SG11201901070YA - Formulations for oral administration of active agents - Google Patents

Formulations for oral administration of active agents

Info

Publication number
SG11201901070YA
SG11201901070YA SG11201901070YA SG11201901070YA SG11201901070YA SG 11201901070Y A SG11201901070Y A SG 11201901070YA SG 11201901070Y A SG11201901070Y A SG 11201901070YA SG 11201901070Y A SG11201901070Y A SG 11201901070YA SG 11201901070Y A SG11201901070Y A SG 11201901070YA
Authority
SG
Singapore
Prior art keywords
international
jerusalem
street
pct
oral administration
Prior art date
Application number
SG11201901070YA
Other languages
English (en)
Inventor
Gregory Burshtein
Ariel Rothner
Phillip M Schwartz
Hillel Galitzer
Original Assignee
Entera Bio Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Entera Bio Ltd filed Critical Entera Bio Ltd
Publication of SG11201901070YA publication Critical patent/SG11201901070YA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/29—Parathyroid hormone, i.e. parathormone; Parathyroid hormone-related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Endocrinology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Nutrition Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Physiology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Diabetes (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
SG11201901070YA 2016-08-17 2017-08-17 Formulations for oral administration of active agents SG11201901070YA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662375989P 2016-08-17 2016-08-17
PCT/IL2017/050920 WO2018033927A1 (en) 2016-08-17 2017-08-17 Formulations for oral administration of active agents

Publications (1)

Publication Number Publication Date
SG11201901070YA true SG11201901070YA (en) 2019-03-28

Family

ID=61196521

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201901070YA SG11201901070YA (en) 2016-08-17 2017-08-17 Formulations for oral administration of active agents

Country Status (14)

Country Link
US (2) US12239691B2 (https=)
EP (1) EP3500291A4 (https=)
JP (4) JP7530173B2 (https=)
KR (4) KR20190039768A (https=)
CN (4) CN116831977A (https=)
AU (2) AU2017311698B2 (https=)
BR (1) BR112019003136A2 (https=)
CA (1) CA3033259A1 (https=)
IL (3) IL264880B2 (https=)
MX (1) MX2019001850A (https=)
NZ (1) NZ751668A (https=)
SG (1) SG11201901070YA (https=)
WO (1) WO2018033927A1 (https=)
ZA (1) ZA201901370B (https=)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113713090B (zh) 2015-02-09 2023-06-02 安特拉贝欧有限公司 骨质疏松症的治疗
IL264880B2 (en) 2016-08-17 2024-09-01 Entera Bio Ltd Preparations for oral administration of active substances
AU2019385420A1 (en) * 2018-11-19 2021-07-08 Spoke Sciences, Inc. N-acylated fatty amino acids to reduce absorption variability in cannabinoid based compositions
EP4122483B1 (en) * 2020-03-18 2025-04-30 Xizang Haisco Pharmaceutical Co., Ltd. Oral pharmaceutical composition
CA3251862A1 (en) * 2022-02-24 2023-08-31 Entera Bio Ltd. Formulations comprising an acid-neutralizing polymer for the oral administration of active agents
WO2023161936A1 (en) * 2022-02-24 2023-08-31 Entera Bio Ltd. Formulations comprising acid-neutralizing polymer for oral administration of growth hormone-releasing hormone
AU2023226092A1 (en) * 2022-02-24 2024-10-03 Entera Bio Ltd. Formulations comprising acid-neutralizing polymer for oral administration of parathyroid hormone
WO2025046589A1 (en) * 2023-08-30 2025-03-06 Entera Bio Ltd. Formulations comprising a combination of acid-neutralizing polymeric and non-polymeric substances for oral administration of active agents

Family Cites Families (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5360793A (en) 1993-05-24 1994-11-01 Sterling Winthrop Inc. Rafting antacid formulation
US6984728B2 (en) 1993-09-24 2006-01-10 Schering Corporation Recombinant infectious laryngotracheitis virus and uses thereof
CN1162917A (zh) 1994-10-07 1997-10-22 伯温德药品服务公司 肠内涂层组合物，用其涂覆的方法和涂覆制品
US5650386A (en) 1995-03-31 1997-07-22 Emisphere Technologies, Inc. Compositions for oral delivery of active agents
CA2220301C (en) 1995-06-02 2006-02-21 Alza Corporation Osmotic device with delayed activation of drug delivery and complete drug release
JP3880093B2 (ja) 1995-08-08 2007-02-14 エーザイ・アール・アンド・ディー・マネジメント株式会社 錠剤
JP3220373B2 (ja) 1995-11-28 2001-10-22 バイエル薬品株式会社 持続性ニフエジピン製剤
IT1282650B1 (it) 1996-02-19 1998-03-31 Jagotec Ag Compressa farmaceutica,caratterizzata da elevato aumento di volume a contatto con liquidi biologici
WO1998009645A1 (en) 1996-09-04 1998-03-12 Dott Research Laboratory Peptide-containing drug compositions for oral administration
US6531152B1 (en) 1998-09-30 2003-03-11 Dexcel Pharma Technologies Ltd. Immediate release gastrointestinal drug delivery system
AU3240900A (en) 1999-02-22 2000-09-04 Emisphere Holdings, Inc. Solid oral dosage form containing heparin or a heparinoid in combination with a carrier
MXPA01008611A (es) 1999-02-26 2003-06-24 Emisphere Tech Inc Compuestos y composiciones para suministrar agentes activos.
EP1175390B1 (en) 1999-04-05 2005-02-02 Emisphere Technologies, Inc. Disodium salts, monohydrates, and ethanol solvates
US6632451B2 (en) 1999-06-04 2003-10-14 Dexcel Pharma Technologies Ltd. Delayed total release two pulse gastrointestinal drug delivery system
KR100788970B1 (ko) 1999-11-05 2007-12-27 에미스페어 테크놀로지스, 인코포레이티드 활성제 전달용 페녹시 카르복시산 화합물 및 조성물
AU1594801A (en) 1999-11-12 2001-06-06 Emisphere Technologies, Inc. Liquid heparin formulation
EP1420827B8 (en) 2001-08-17 2009-12-23 Novartis AG 5-cnac as oral delivery agent for parathyroid hormone fragments
NZ532597A (en) 2001-11-13 2006-04-28 Emisphere Tech Inc Phenoxy amine compounds and compositions for delivering active agents
AU2002352974A1 (en) 2001-11-29 2003-06-10 Emisphere Technologies, Inc. Formulations for oral administration of cromolyn sodium
JP4417110B2 (ja) * 2001-12-19 2010-02-17 株式会社三和化学研究所 放出制御型成型品
US20030198666A1 (en) 2002-01-07 2003-10-23 Richat Abbas Oral insulin therapy
US20050054557A1 (en) 2002-05-09 2005-03-10 Goldberg Michael M. Compositions for delivering parathyroid hormone and calcitonin
PE20040724A1 (es) 2002-08-01 2004-12-06 Novartis Ag Composicion para la administracion oral de calcitonina
US20070155664A1 (en) * 2003-07-04 2007-07-05 Nycomed Danmark A/S Parathyroid hormone (pth) containing pharmaceutical compositions for oral use
JP2005281231A (ja) 2004-03-30 2005-10-13 Bioserentack Co Ltd 小腸ターゲットタイプの経口ｄｄｓ製剤
US20060052306A1 (en) 2004-05-10 2006-03-09 Nastech Pharmaceutical Company Inc. GRAS composition for enhanced mucosal delivery of parathyroid hormone
WO2006124047A2 (en) 2004-08-13 2006-11-23 Emisphere Technologies, Inc. Pharmaceutical formulations containing microparticles or nanoparticles of a delivery agent
JP2006111558A (ja) 2004-10-14 2006-04-27 Bioserentack Co Ltd 多層構造を有する錠剤状の小腸粘膜付着性経口製剤
BRPI0518125A (pt) * 2004-11-19 2008-10-28 Smithkline Beecham Corp produto farmacêutico
WO2006076692A1 (en) 2005-01-12 2006-07-20 Emisphere Technologies, Inc. Compositions for buccal delivery of parathyroid hormone
ES2540929T3 (es) * 2005-02-01 2015-07-14 Emisphere Technologies, Inc. Sistema de administración de retención gástrica y liberación controlada
US8673352B2 (en) 2005-04-15 2014-03-18 Mcneil-Ppc, Inc. Modified release dosage form
JP5123471B2 (ja) 2005-08-18 2013-01-23 帝人ファーマ株式会社 用量調整が容易な製剤
EP1933862B1 (en) 2005-09-06 2014-03-26 Oramed Pharmaceuticals Inc. Methods and compositions for oral administration of proteins
US7629331B2 (en) 2005-10-26 2009-12-08 Cydex Pharmaceuticals, Inc. Sulfoalkyl ether cyclodextrin compositions and methods of preparation thereof
RU2469709C2 (ru) 2005-11-17 2012-12-20 Новартис Аг Фармацевтическая композиция
US20070178155A1 (en) 2006-01-31 2007-08-02 Jiang David Yihai Preparation for gastric buoyant sustained drug release dosage form
KR101191322B1 (ko) * 2006-04-07 2012-10-16 메리온 리서치 Ⅲ 리미티드 증진제를 함유하는 고형 경구용 투여 제형
WO2007121318A2 (en) * 2006-04-12 2007-10-25 Emisphere Technologies, Inc. Formulations for delivering insulin
WO2007121471A2 (en) 2006-04-18 2007-10-25 Emisphere Technologies, Inc. Dialkyl ether delivery agents
EP2079456B1 (en) * 2007-04-04 2012-12-05 Sigmoid Pharma Limited Pharmaceutical cyclosporin compositions
US20100303901A1 (en) 2007-04-26 2010-12-02 Eyal Shimoni Oral delivery of proteins and peptides
US20100285098A1 (en) 2007-09-11 2010-11-11 Haley Jeffrey T Adhering troches with santacid for treatment of throat esophagus and stomach
WO2009080764A2 (en) 2007-12-20 2009-07-02 Abylnx N.V. Oral or nasal administration of compounds comprising amino acid sequences
IT1393244B1 (it) * 2008-07-18 2012-04-12 Universita' Degli Studi Di Milano Sistema per il rilascio al colon di farmaci suscettibili di degradazione enzimatica e/o scarsamente assorbiti nel tratto gastrointestinale
RU2494755C2 (ru) 2008-08-18 2013-10-10 Интера Био Лтд. Способы и композиции для перорального введения белков
US20110182985A1 (en) * 2010-01-28 2011-07-28 Coughlan David C Solid Pharmaceutical Composition with Enhancers and Methods of Preparing thereof
AU2011239935A1 (en) 2010-04-16 2012-11-08 Novartis Ag Methods and compositions for improving implant osseointegration
MX377589B (es) 2010-12-16 2025-03-10 Novo Nordisk As Composiciones sólidas que comprenden agonista de glp-1 y sal del ácido n-(8-(2-hidroxibenzoil)amino)caprílico.
WO2013032934A1 (en) 2011-08-26 2013-03-07 Aegis Therapeutics, Llc Compositions and methods thereof for oral administration of drugs
US9402877B2 (en) 2011-11-04 2016-08-02 Xion Pharmaceuticals Corporation Methods and compositions for oral administration of melanocortin receptor agonist compounds
JP6517690B2 (ja) * 2012-06-20 2019-05-22 ノヴォ ノルディスク アー／エス ペプチド及び送達剤を含む錠剤製剤
US9803731B2 (en) 2014-04-24 2017-10-31 American Axle & Manufacturing, Inc. Actuator device having cam and follower and controller configured to employ rate-based methodology to identify positioning of follower on cam at predetermined location
EP2975118B1 (en) 2014-07-16 2016-08-24 Johann Wolfgang Goethe-Universität, Frankfurt am Main Generation of a mesenchymal stromal cell bank from the pooled mononuclear cells of multiple bone marrow donors
CN113713090B (zh) 2015-02-09 2023-06-02 安特拉贝欧有限公司 骨质疏松症的治疗
IL264880B2 (en) 2016-08-17 2024-09-01 Entera Bio Ltd Preparations for oral administration of active substances
JP7419862B2 (ja) 2020-02-14 2024-01-23 株式会社リコー 潤滑剤供給装置、プロセスカートリッジ、及び、画像形成装置

Also Published As

Publication number Publication date
IL264880B2 (en) 2024-09-01
IL312218A (en) 2024-06-01
MX2019001850A (es) 2019-05-15
JP7736834B2 (ja) 2025-09-09
AU2017311698B2 (en) 2024-09-05
JP7546622B2 (ja) 2024-09-06
WO2018033927A1 (en) 2018-02-22
JP2025114692A (ja) 2025-08-05
IL321113A (en) 2025-07-01
BR112019003136A2 (pt) 2019-05-21
IL312218B1 (en) 2025-07-01
KR102832566B1 (ko) 2025-07-09
CN109862906A (zh) 2019-06-07
JP2024054222A (ja) 2024-04-16
AU2024211004A1 (en) 2024-09-05
NZ751668A (en) 2022-07-29
KR20240093678A (ko) 2024-06-24
IL312218B2 (en) 2025-11-01
US20190209657A1 (en) 2019-07-11
IL264880A (en) 2019-04-30
CN116831977A (zh) 2023-10-03
AU2017311698A1 (en) 2019-04-04
CN116831978A (zh) 2023-10-03
CA3033259A1 (en) 2018-02-22
JP2022126766A (ja) 2022-08-30
CN116850132A (zh) 2023-10-10
KR20190039768A (ko) 2019-04-15
US20240415936A1 (en) 2024-12-19
EP3500291A1 (en) 2019-06-26
EP3500291A4 (en) 2020-03-11
KR20230088854A (ko) 2023-06-20
IL264880B1 (en) 2024-05-01
KR20240134254A (ko) 2024-09-06
JP7530173B2 (ja) 2024-08-07
KR102832565B1 (ko) 2025-07-09
US12239691B2 (en) 2025-03-04
AU2024211004B2 (en) 2026-04-09
ZA201901370B (en) 2025-07-30
JP2019524836A (ja) 2019-09-05

Similar Documents

Publication Publication Date Title
SG11201901070YA (en) Formulations for oral administration of active agents
SG11201803920TA (en) Compounds and compositions useful for treating disorders related to ntrk
SG11201809082WA (en) Nlrp3 modulators
SG11201907604UA (en) Crystalline forms of the 4-pyrimidinesulfamide derivative aprocitentan
SG11201901063SA (en) Therapeutic agents for neurodegenerative diseases
SG11201908540PA (en) Stable antibody formulation
SG11201909960UA (en) Methods for improving memory and cognition and for treating memory and cognitive disorders
SG11201900633XA (en) Piperidine cxcr7 receptor modulators
SG11201811470PA (en) Pyrazolopyrimidine derivatives as kinase inhibitor
SG11201808003RA (en) Bromodomain inhibitors
SG11201807784SA (en) 3-desoxy derivative and pharmaceutical compositions thereof
SG11201407580YA (en) Composition comprising two antibodies engineered to have reduced and increased effector function
SG11201903450YA (en) Methods for treating muscle wasting and bone disease using novel hybrid actriib ligand trap proteins
SG11201807597UA (en) Methods of treating depression using orexin-2 receptor antagonists
SG11201804673WA (en) Novel anti-claudin antibodies and methods of use
SG11201907583TA (en) Methods for treating complement-mediated diseases and disorders
SG11201808676RA (en) Methods of treating pediatric cancers
SG11201804721SA (en) Modulators of complement activity
SG11201907159SA (en) Treatment of hidradenitis suppurativa
SG11201906164RA (en) Bicyclic inhibitors of histone deacetylase
SG11201907153RA (en) Topical formulations and methods
SG11201806127XA (en) Pharmaceutical or nutritional combination comprising beta-hydroxy-betamethylbutyrate
SG11201804587QA (en) Isoindole compounds
SG11201901048VA (en) Pharmaceutical compositions and uses directed to lysosomal storage disorders
SG11201810358YA (en) Compositions and methods for treating negative symptoms in non-schizophrenic patients